UBS AM Increases Stake in Soleno Therapeutics

Summary

UBS Asset Management, a division of UBS AM Americas, increased its holdings in Soleno Therapeutics, Inc. (NASDAQ: SLNO) by 24.8% in the fourth quarter, acquiring 5,462 shares to hold a total of 27,504 shares valued at $1.236 million. Other institutional investors also increased their holdings. Analysts have a positive outlook on the company, with multiple buy ratings and an average target price of $106.78. Soleno’s shares opened at $77.73, with a 52-week range of $36.93 to $80.99. The company reported a loss of $0.95 per share, exceeding expectations.Market Beat

Impact Analysis

This is a company-level event as it pertains to UBS Asset Management’s increased stake in Soleno Therapeutics. The direct impact involves potential investor confidence, indicated by enhanced institutional holdings. The positive analyst ratings and target prices suggest optimism about Soleno’s future performance, potentially driving further interest and stock price appreciation. However, the reported loss per share introduces risks, indicating financial challenges that could affect investor sentiment. The opportunity lies in Soleno’s perceived growth potential, reflected in its stock price range and analyst projections.Market Beat